Profile data is unavailable for this security.
About the company
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
- Revenue in USD (TTM)5.62bn
- Net income in USD1.43bn
- Incorporated1999
- Employees19.80k
- LocationEdwards Lifesciences CorpOne Edwards WayIRVINE 92614United StatesUSA
- Phone+1 (949) 250-2500
- Fax+1 (302) 655-5049
- Websitehttps://www.edwards.com
Mergers & acquisitions
| Acquired company | EW:NYQ since announced | Transaction value |
|---|---|---|
| JC Medical Inc | 1.64% | -- |
| JenaValve Technology Inc | -19.53% | -- |
| Endotronix Inc | -19.53% | 1.65bn |
| Innovalve Bio Medical Ltd | -23.01% | -- |
